Your Yourlocation: Home > The combination therapy of tiotropium bromide(136310-93-5) with formoterol in the treatment of COPD is worthy of promotion

Tiotropium bromide(136310-93-5) mainly acts on the M1 and M3 receptors, competitively and reversibly inhibits M3 receptor binding to acetylcholine in the respiratory tract, relaxes the smooth muscle, whereas the half-life of dissociation with the M3 receptor is longer than ipratropium bromide, Effective inhibition of cholinergic airway contraction, strong airway to maintain smooth 24 hours to reduce the gas trapped, providing patients with a day of continuous exercise tolerance good.

It has been reported that anticholinergics and β2 agonists have a synergistic effect. Anticholinergic receptors are mainly distributed in the central airway, β2 receptors are mainly distributed in the peripheral airway, the two combined treatment of COPD, respectively, on the parasympathetic and sympathetic nerve, can simultaneously expand the central airway and peripheral airway, thereby improve efficacy and improve airway obstruction. In combination with formoterol, the effect of tiotropium bromide(136310-93-5) on diastolic bronchus is more rapid. The combination of two drugs can not only improve lung function, but did not increase the incidence of adverse reactions.

The results of this study show that tiotropium combined with formoterol inhalation therapy, compared with single-use formoterol inhalation, the effect is more significant. The lung function of the treatment group was better than that of the control group (P <0105). Indicating that tiotropium combined with formoterol inhalation treatment of COPD than a single drug efficacy is more certain, worthy of promotion.

COPD is a chronic airway inflammation caused by incomplete reversible airflow limitation disease. COPD maintenance therapy aims to relieve symptoms and reduce the number of acute exacerbations. Therefore, the maintenance of standardized treatment of patients, improve lung function, delaying the development of the disease as an important measure. Anticholinergic drugs because of its long duration of bronchodilation, fewer adverse reactions, long-term use of non-tolerance, was recommended as first-line treatment of patients with COPD maintenance therapy in daily life with tiotropium bromide(136310-93-5) will reduce COPD patients of the economic burden.

Address: TEL:0531-82375879 Tiotropium Bromide
© Copyright(C)2014 JINAN DEXINJIA BIO & TECH CO., LTD All Rights Reserved